Mono-Methyl-Histone H3 (K37) Antibody

What is the biological significance of H3K37me1 in chromatin regulation?

H3K37me1 plays a critical role in regulating DNA replication, particularly in origin licensing. Research has demonstrated that H3K37me1 functions by hindering Mcm2 interaction with chromatin, effectively maintaining low levels of MCM outside of replication origins and preventing DNA replication events at non-canonical sites . This modification has been identified through various mass spectrometry studies in both yeast and human cells, indicating its conservation across species . Unlike some histone modifications that promote transcriptional activation, H3K37me1 appears to be associated with regulating proper DNA replication timing and preventing inappropriate origin firing.

Which enzymes are responsible for catalyzing H3K37 mono-methylation?

H3K37 mono-methylation (H3K37me1) is catalyzed by Set1p and Set2p methyltransferases . These enzymes add a single methyl group specifically to lysine 37 on histone H3. This enzymatic activity represents part of the complex regulatory system controlling chromatin structure and DNA accessibility. Understanding these enzymatic pathways is crucial for researchers investigating epigenetic regulation mechanisms and potential therapeutic interventions targeting histone modifications.

How does H3K37me1 differ functionally from other histone H3 lysine methylations?

While several lysine residues on histone H3 can be methylated (including K4, K9, K27, K36, and K79), H3K37me1 appears to have a distinct regulatory function in DNA replication . Unlike H3K4me3, which is generally associated with active transcription, or H3K9me3, which typically marks heterochromatin, H3K37me1 specifically regulates replication origin licensing by affecting MCM helicase interaction with chromatin . This specificity highlights the importance of studying individual histone modifications rather than generalizing about methylation effects. Notably, H3K37me1 can coexist with H3K36me1, suggesting potential cooperative functions between neighboring modifications .

How can I verify the specificity of an H3K37me1 antibody for my research?

Validating antibody specificity is critical for histone modification research. For H3K37me1 antibodies, employ these methodological approaches:

• Dot blot analysis: Test the antibody against peptides containing H3K37me1 modifications versus unmodified peptides and peptides with other modifications (H3K36me1, H3K37me2, H3K37me3, H3K37ac) . The antibody should strongly recognize H3K37me1 peptides with minimal cross-reactivity.

• Western blot with controls: Include samples from wild-type cells alongside H3K37A mutants (where lysine 37 is replaced with alanine) . A specific antibody will show reactivity with wild-type but not with the mutant.

• ELISA testing: Quantitatively measure antibody specificity toward H3K37me1-modified peptides versus unmodified peptides . A several-fold higher reactivity confirms specificity.

• Chromatin immunoprecipitation (ChIP): Compare ChIP results between wild-type and H3K37A mutant cells . Specific enrichment should only be observed in wild-type samples.

• Recombinant protein controls: Test reactivity against recombinant H3 produced in bacteria (which lacks modifications) versus H3 from eukaryotic cells .

What factors should I consider when selecting between polyclonal and monoclonal H3K37me1 antibodies?

When choosing between polyclonal and monoclonal H3K37me1 antibodies, consider these research-specific factors:

Polyclonal Antibodies (e.g., ab272160 ):

• Advantages: Recognize multiple epitopes, potentially increasing sensitivity; useful for applications like immunoprecipitation where antigen retrieval may be challenging.

• Considerations: Batch-to-batch variation requires validation of each lot; may have higher background in some applications.

• Best Applications: Western blotting, immunoprecipitation, and preliminary studies.

Monoclonal Antibodies (e.g., EPR20970 ):

• Advantages: Consistent epitope recognition between batches; typically higher specificity with lower background; reliable for quantitative applications.

• Considerations: May be less robust if the specific epitope is masked or modified; potentially lower signal in some applications.

• Best Applications: Quantitative immunofluorescence, ChIP-seq, and studies requiring high reproducibility.

How should I validate antibody cross-reactivity with neighboring modifications like H3K36me1?

Cross-reactivity validation is especially important for H3K37me1 antibodies due to the proximity of other frequently modified residues like K36. Implement this methodological approach:

• Peptide competition assays: Pre-incubate the antibody with various modified peptides (H3K36me1, H3K36me2, H3K36me3, H3K37me2, H3K37me3) before application in your experiment. If signal is reduced only with H3K37me1 peptide competition, this confirms specificity .

• Recombinant protein panel testing: Use western blot analysis with recombinant H3 proteins containing specific modifications:

  • Unmodified H3

  • H3K37me1

  • H3K37me2

  • H3K37me3

  • H3K36me1

  • H3K36me2

  • H3K36me3

  A specific antibody should only detect the H3K37me1-modified protein .

• Dot blot matrix: Create a comprehensive dot blot with increasing concentrations (1, 10, 100 picomoles) of differentially modified peptides to assess potential cross-reactivity quantitatively .

Expected pattern for a highly specific H3K37me1 antibody based on ab272160 validation data

What are the optimal conditions for using H3K37me1 antibodies in Western blotting?

For optimal Western blotting results with H3K37me1 antibodies, follow this methodological protocol:

• Sample preparation:

  • Extract histones using acid extraction protocol to enrich for basic proteins

  • Load 20-30 μg of total protein or 2-5 μg of purified histones

  • Include positive controls (wild-type cells) and negative controls (H3K37A mutants if available)

• Gel electrophoresis:

  • Use 15-20% SDS-PAGE gels to properly resolve the low molecular weight histones

  • Run at 70V (stacking)/90V (resolving) for optimal separation

• Transfer conditions:

  • Transfer to nitrocellulose membrane at 150mA for 50-90 minutes

  • Use standard transfer buffer with 20% methanol

• Blocking and antibody incubation:

  • Block with 5% non-fat milk in TBS for 1.5 hours at room temperature

  • Incubate with primary H3K37me1 antibody at 1:1000 dilution overnight at 4°C

  • Wash with TBS-0.1% Tween (3 x 5 minutes)

  • Incubate with HRP-conjugated secondary antibody at 1:10,000 dilution for 1-1.5 hours at room temperature

• Detection:

  • Develop using enhanced chemiluminescence (ECL) detection system

  • Expected band size: 15-17 kDa

Common cell lines showing detectable H3K37me1 signal include HeLa, Jurkat, HepG2, NIH/3T3, and 293T . When comparing different experimental conditions, maintain identical antibody concentrations and exposure times to ensure quantitative comparability.

How should I optimize chromatin immunoprecipitation (ChIP) protocols for H3K37me1 studies?

For successful H3K37me1 ChIP experiments, implement these methodological optimizations:

• Crosslinking optimization:

  • Standard formaldehyde crosslinking (1% for 10 minutes) works well for most histone modifications

  • For H3K37me1, which may be involved in DNA replication regulation, dual crosslinking with 1.5 mM EGS (ethylene glycol bis[succinimidylsuccinate]) for 30 minutes followed by 1% formaldehyde for 10 minutes can improve capture of protein complexes associated with replication machinery

• Chromatin fragmentation:

  • Sonicate to generate fragments of 200-500 bp

  • Verify fragmentation by agarose gel electrophoresis

• Antibody amount and incubation:

  • Use 2-5 μg of H3K37me1 antibody per ChIP reaction

  • Based on immunoprecipitation protocols, a dilution of 1:25 is recommended

  • Incubate overnight at 4°C with rotation

• Controls:

  • Input chromatin (10% of ChIP material)

  • IgG negative control

  • ChIP with antibody against total H3 (normalization control)

  • If available, H3K37A mutant cells (negative control)

• Washing conditions:

  • Low salt wash buffer: 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl

  • High salt wash buffer: Same as low salt but with 500 mM NaCl

  • LiCl wash buffer: 0.25 M LiCl, 1% NP-40, 1% deoxycholic acid, 1 mM EDTA, 10 mM Tris-HCl pH 8.0

  • TE buffer: 10 mM Tris-HCl, 1 mM EDTA, pH 8.0

• Analysis suggestions:

  • For targeted analysis, design primers around replication origins or regions where DNA replication regulation occurs

  • For genome-wide profiling, ChIP-seq analysis should focus on origin recognition complex (ORC) binding sites and replication initiation zones

What are the recommended protocols for immunofluorescence detection of H3K37me1?

For optimal immunofluorescence detection of H3K37me1, follow this detailed protocol:

• Cell preparation and fixation:

  • Culture cells on glass coverslips or chamber slides

  • Fix with 4% paraformaldehyde for 10 minutes at room temperature

  • Permeabilize with 0.1% Triton X-100 for 10 minutes

• Blocking and antibody incubation:

  • Block with 5% normal goat serum in PBS for 1 hour at room temperature

  • Incubate with primary H3K37me1 antibody at 1:100-1:200 dilution overnight at 4°C

  • Wash 3 times with PBS (5 minutes each)

  • Incubate with fluorophore-conjugated secondary antibody (e.g., Alexa Fluor 488) at 1:1000 dilution for 1 hour at room temperature

• Counterstaining:

  • Counterstain nuclei with DAPI (1 μg/ml)

  • For co-localization studies, consider counterstaining with antibodies against:

    • Alpha-tubulin (cytoskeletal marker)

    • Replication proteins (MCM2, PCNA, etc.) given H3K37me1's role in replication

• Imaging parameters:

  • Use confocal microscopy for highest resolution

  • Capture z-stacks to ensure complete nuclear visualization

  • For quantitative analysis, maintain identical exposure settings across all samples

• Expected patterns:

  • H3K37me1 typically shows nuclear staining

  • In NIH/3T3 cells, a distinct nuclear pattern has been observed

  • Cell cycle-dependent patterns may be present given H3K37me1's role in DNA replication

• Controls:

  • Secondary antibody only (background control)

  • Peptide competition (specificity control)

  • If available, H3K37A mutant cells (negative control)

How does H3K37me1 distribution change during different phases of the cell cycle?

H3K37me1 distributions show significant cell cycle-dependent patterns due to its role in regulating DNA replication origin licensing . A methodological approach to investigating these dynamics should include:

• Cell synchronization protocols:

  • Double thymidine block for G1/S boundary synchronization

  • Nocodazole treatment for mitotic arrest

  • Serum starvation for G0/G1 enrichment

• Time-course analysis:

  • Following synchronization release, collect cells at defined intervals (e.g., 0, 2, 4, 6, 8, 10, 12 hours)

  • Perform Western blotting, ChIP-seq, or immunofluorescence at each timepoint

  • Verify cell cycle position using flow cytometry with propidium iodide staining

• Expected patterns:

  • H3K37me1 levels likely fluctuate during S-phase when replication origin licensing and firing are regulated

  • Lower levels may be expected in G1 when origins are being licensed

  • Potential increase in late S-phase to prevent re-replication

• Co-localization analysis:

  • Examine spatial relationship between H3K37me1 and proteins involved in replication:

    • Pre-replication complex components (MCM2-7, CDC6, CDT1)

    • Origin recognition complex (ORC) proteins

    • PCNA (active replication marker)

• Genome-wide distribution changes:

  • Perform ChIP-seq at different cell cycle stages

  • Analyze distribution relative to known replication origins

  • Correlate with replication timing domains

This methodological approach can reveal how H3K37me1 contributes to the temporal regulation of DNA replication throughout the cell cycle, potentially identifying regulatory mechanisms that prevent inappropriate origin firing.

What is the interplay between H3K37me1 and H3K36me1 in regulating chromatin function?

The proximity of lysines 36 and 37 on histone H3 suggests potential functional interactions between their modifications. Research indicates that H3K37me1 can coexist with H3K36me1 , suggesting complex regulatory relationships. To investigate this interplay, implement these methodological approaches:

• Sequential ChIP (Re-ChIP) analysis:

  • First round: Immunoprecipitate with H3K36me1 antibody

  • Second round: Re-immunoprecipitate with H3K37me1 antibody

  • Analyze genomic regions containing both modifications

• Mass spectrometry analysis:

  • Perform bottom-up proteomics to identify peptides containing both modifications

  • Quantify relative abundance of singly-modified versus doubly-modified peptides

  • Compare across different cellular conditions and genetic backgrounds

• Genetic interaction studies:

  • Create yeast strains with mutations affecting each modification:

    • H3K36A (prevents K36 methylation)

    • H3K37A (prevents K37 methylation)

    • Set1/Set2 deletions (enzymes catalyzing H3K37me1)

    • Set2/SETD2 mutations (enzymes catalyzing H3K36 methylation)

  • Analyze phenotypes of single versus double mutants to identify synthetic interactions

• Genome-wide distribution analysis:

  • Compare ChIP-seq profiles of H3K36me1 versus H3K37me1

  • Identify regions of overlap versus unique distribution

  • Correlate with transcription, replication timing, and chromatin states

• Functional enzyme studies:

  • Test whether prior methylation at one residue affects enzymatic activity at the neighboring residue

  • Use in vitro assays with purified methyltransferases and synthetic H3 peptides with defined modifications

Current research suggests that while H3K36me1 contributes to MCM helicase activation , H3K37me1 appears to hinder Mcm2 interaction with chromatin . This apparent opposing function at adjacent residues suggests a potential "methylation switch" mechanism that fine-tunes replication regulation through the balance of these modifications.

How do Set1 and Set2 enzymes specifically recognize and methylate H3K37 versus other lysine residues?

Understanding the molecular basis for the specificity of Set1 and Set2 toward H3K37 represents an important question in epigenetic regulation. To investigate this enzyme-substrate specificity, employ these methodological approaches:

• Structural analysis:

  • Perform X-ray crystallography or cryo-EM studies of Set1/Set2 in complex with H3 peptides

  • Identify key residues in the enzyme active site that contact H3K37

  • Compare with structures of other lysine methyltransferases (KMTs)

• Mutational analysis:

  • Create point mutations in the substrate recognition domain of Set1/Set2

  • Test methyltransferase activity against H3K37 versus other lysine residues

  • Identify critical residues that confer specificity

• Peptide array analysis:

  • Generate arrays of H3 peptides with systematic mutations around K37

  • Test methylation activity of purified Set1/Set2

  • Identify sequence determinants required for recognition

• Molecular dynamics simulations:

  • Model enzyme-substrate interactions

  • Simulate binding energy differences between K37 and other lysine residues

  • Identify conformational changes during catalysis

• Enzyme kinetics:

  • Measure kinetic parameters (Km, kcat) for Set1/Set2 against different lysine substrates

  • Compare catalytic efficiency (kcat/Km) for H3K37 versus other sites

  • Determine if specificity is driven by binding affinity or catalytic rate

The amino acid context surrounding K37 likely plays a crucial role in determining enzyme specificity. While Set1 is primarily known for H3K4 methylation in many contexts, its additional activity toward H3K37 suggests either a secondary binding mode or context-dependent activity. Similarly, Set2, typically associated with H3K36 methylation, may recognize H3K37 due to its proximity to K36, potentially as part of a processive methylation mechanism along the H3 tail.

Why might I observe inconsistent H3K37me1 antibody signals in Western blotting, and how can I resolve this?

Inconsistent Western blot signals with H3K37me1 antibodies can stem from several technical factors. Apply these methodological solutions to common problems:

• Problem: High background or non-specific bands

  Solutions:

  • Increase blocking time to 2 hours or overnight at 4°C using 5% non-fat milk

  • Reduce primary antibody concentration (try 1:2000 instead of 1:1000)

  • Add 0.1% Tween-20 to antibody dilution buffers

  • Use highly purified histone fractions rather than whole cell lysates

  • Include competitive peptides to confirm specificity

• Problem: Weak or absent signal for H3K37me1

  Solutions:

  • Enrich histones using acid extraction (0.2N HCl for 30 minutes on ice)

  • Add protease inhibitors, deacetylase inhibitors, and phosphatase inhibitors during extraction

  • Reduce gel percentage to 15% for better transfer efficiency

  • Use PVDF membranes instead of nitrocellulose for stronger protein binding

  • Extend primary antibody incubation to 48 hours at 4°C

  • Try enhanced chemiluminescence substrates with higher sensitivity

• Problem: Variability between experiments

  Solutions:

  • Standardize histone extraction protocols

  • Use recombinant H3K37me1 as a positive control for normalization

  • Maintain consistent antibody lot numbers between experiments

  • Include loading controls using total H3 antibodies on the same blot

  • Quantify band intensity using digital imaging software with background subtraction

• Problem: Different results between cell types

  Solutions:

  • Optimize extraction protocols for each cell type

  • Normalize H3K37me1 signals to total H3 levels

  • Consider cell cycle synchronization as H3K37me1 levels may vary during the cell cycle

  • Verify antibody reactivity in each species (human, mouse, rat)

Recommendations based on published Western blot protocols

How can I distinguish between technical artifacts and biological variability when analyzing H3K37me1 ChIP-seq data?

Differentiation between technical artifacts and genuine biological variation in H3K37me1 ChIP-seq requires a systematic methodological approach:

• Experimental design controls:

  • Include input DNA controls for normalization

  • Perform ChIP with IgG antibodies (background control)

  • Include spike-in chromatin from a different species for cross-sample normalization

  • Process technical replicates to assess variability

  • Perform ChIP using total H3 antibodies to control for nucleosome occupancy

• Quality control metrics:

  • Calculate enrichment over input at known positive regions

  • Assess strand cross-correlation to verify fragment size distribution

  • Compute fraction of reads in peaks (FRiP) score

  • Evaluate peak concordance between replicates using irreproducible discovery rate (IDR)

• Bioinformatic filtering steps:

  • Remove blacklisted genomic regions prone to artifacts

  • Filter out peaks with unusual read distribution patterns

  • Implement GC content normalization for sequencing bias correction

  • Compare enrichment patterns with published datasets when available

• Validation strategies:

  • Confirm selected peaks using ChIP-qPCR

  • Cross-reference with other histone modifications datasets

  • Validate biological findings in different cell types

  • Use genetic manipulation (e.g., Set1/Set2 depletion) to confirm specificity

• Biological versus technical variation discrimination:

  • Technical artifacts typically have characteristic patterns:

    • Extreme GC content regions

    • Repetitive elements

    • Centromeres and telomeres

    • Regions with mappability issues

  • Biological variation patterns frequently:

    • Correlate with functional genomic elements

    • Show cell type-specific patterns

    • Respond logically to experimental perturbations

    • Correlate with other functional data (transcription, replication timing)

When analyzing H3K37me1 ChIP-seq data specifically, focus on regions associated with DNA replication origins and MCM protein binding sites, given the known role of H3K37me1 in regulating origin licensing .

What are the critical controls needed when performing immunofluorescence studies to detect dynamic changes in H3K37me1?

For reliable immunofluorescence detection of dynamic H3K37me1 changes, implement these critical methodological controls:

• Antibody specificity controls:

  • Peptide competition: Pre-incubate antibody with H3K37me1 peptide to block specific binding

  • H3K37A mutant cells (if available): Should show no signal

  • Samples with Set1/Set2 knockdown: Should show reduced signal

  • Secondary antibody only: To assess background fluorescence

• Technical controls:

  • Fixation controls: Compare different fixation methods (paraformaldehyde vs. methanol)

  • Titration series: Test different antibody dilutions (1:50, 1:100, 1:200, 1:500)

  • Z-stack imaging: Ensure complete nuclear visualization

  • Fluorescence intensity standards: Include calibration beads for quantitative analysis

• Biological controls for dynamic studies:

  • Cell cycle markers: Co-stain with cyclin antibodies or PCNA to identify cell cycle phases

  • Synchronized populations: Compare cells at defined cell cycle stages

  • Treated vs. untreated: Include samples with replication inhibitors (e.g., hydroxyurea)

  • Genetic perturbations: Include cells with altered H3K37me1 regulation

• Imaging controls:

  • Multi-channel bleed-through controls: Image single-color samples with all detection channels

  • Photobleaching controls: Measure signal decay during repeated imaging

  • Identical acquisition parameters: Maintain consistent exposure, gain, and offset settings

  • Randomization: Blind sample identity during imaging and analysis

• Quantification controls:

  • Nuclear segmentation verification: Validate automated nuclei identification

  • Threshold consistency: Apply identical thresholding across all samples

  • Background subtraction: Measure and subtract non-specific signal

  • Normalization: Normalize H3K37me1 signal to total H3 when possible

The inclusion of proper controls is particularly important when studying dynamic changes in H3K37me1, as subtle differences in signal intensity may represent significant biological regulation related to DNA replication timing or cell cycle progression .